Year: 2025
Type: article
Abstract: ediatric alopecia areata (AA) is a chronic autoimmune disease of the hair follicles characterized by nonscarring hair loss.Its incidence in children in the United States ranges from 13.6 to 33.5 per 100,000 person-years, with a prevalence of 0.04% to 0.11%. 1 Alopecia areata has important effects on quality of life, particularly in children.Hair loss at an early age can decrease participation in school, sports, and extracurricular activities 2 and is associated with increased rates of comorbid anxiety and depression.3 Families also experience psychosocial stress, often comparable to other chronic pediatric illnesses.4 Thus, management requires not only medical therapy but also psychosocial support and school-based accommodations.Systemic therapies for treatment of AA in adolescents and adults are increasingly available, including US Food and Drug Administration (FDA)-approved Janus kinase (JAK) inhibitors such as baricitinib, deuruxolitinib (for adults), and ritlecitinib (for adolescents and adults); however, no systemic therapies have been approved by the FDA for children younger than 12 years.The therapeutic gap is most acute for those aged 6 to 11 years, for whom the psychosocial burden is high but treatment options are limited.3 This article highlights options and strategies for managing AA in children aged 6 to 11 years, emphasizing supportive and psychosocial care (including camouflage techniques), topical therapies, and off-label systemic approaches.
Source: Cutis
DOI: 10.12788/cutis.1302
Author: Leslie Castelo-Soccio
Institutions: Children's National, George Washington University
Language: English
Topic: Hair Growth and Disorders
Subfield: Urology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7124308339
FWCI:
Cites:
Cited by:
Related to: